Changzhou Smart-Lifesciences Biotechnology Co.,Ltd.

Since the outbreak of the novel coronavirus in January, the number of confirmed cases of COVID-19 in China has exceeded 80,000. As various regions have taken effective measures to actively respond, many places have achieved zero growth for several consecutive days, which is the result of concerted efforts. At the same time, new breakthroughs have been made in the research and development of virus antibodies.

On the afternoon of February 24, the joint emergency response team for COVID-19, composed of Lan Fei's research group at the Institute of Biomedical Sciences of Fudan University, the Shanghai Public Health Clinical COVID-19 Research Team affiliated to Fudan University, and Shanghai Aiyue Biotechnology, successfully obtained the first "fully human antibody" for COVID-19. This research provides an effective and rapid R&D plan and candidate antibodies for the development of fully human neutralizing antibody drugs.

As a company focusing on the research and development and production of bio-microspheres and supporting biological reagents, Changzhou Smart-Lifesciences Biotechnology actively connected with the above-mentioned scientific research institutions and teams at the beginning of the project to assist in the development of the new coronavirus antibody project. We undertook the purification and large-scale production of both antibody screening reagents and new coronavirus antibodies. As a deep cultivator in the field of protein purification, after several years of development, the company's ligand production-eukaryotic expression and purification platform has become mature enough to ensure the large-scale production and supply of eukaryotic expression proteins and antibodies. At present, our scientific research team has obtained nearly 100 fully human antibodies for the new coronavirus and screened out more than a dozen antigen-binding positive antibodies. Through the expression and purification of the antibodies we are responsible for, the seamless link between antibody screening and recombinant antibody expression is achieved quickly and efficiently.

The advantages of recombinant antibodies are: by using gene recombination technology, the monoclonal antibodies synthesized and expressed in vitro have a short cycle, low immunogenicity, good repeatability, and can be quickly prepared in large quantities. Immuno-agarose magnetic beads can achieve rapid throughput detection and purification of antibodies, and protein A or protein G agarose gel media can quickly purify antibodies from cell culture media in one step, with a purity of more than 95%.

In particular, the alkaline-resistant Protein At Beads 4FF uses a stable alkaline-resistant protein A ligand and directional coupling, has low ligand shedding, and can be regenerated with 0.1-0.5 M NaOH solution and can be reused many times.

Changzhou Smart-Lifesciences Biotechnology can not only provide customers with high-quality fillers, but also provide customers with upstream and downstream supporting biological reagents and better experimental solutions. As the research and development of viral antibodies continues to deepen, we look forward to providing more products and technical support to all scientific researchers, and work together to overcome the epidemic!